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Abstract
Neurocognitive impairment (NCI) is common in people agingwith HIV and can adversely affect health-related quality of life. However,
early NCI may be largely asymptomatic and neurocognitive function is rarely assessed in the context of routine clinical care. In this
study, we considered the utility of two assessment tools as screens for NCI in patients attending a community-based clinic (N5 58;
mean age5 57 years): the Montreal Cognitive Assessment (MoCA) and a 3-item cognitive concerns questionnaire derived from the
HIVDementia Scale. Health-related quality of life and depression/anxiety were alsomeasured. Indication of NCI using theMoCAwas
more prevalent compared to the 3-itemquestionnaire andwas associatedwith the patients’ initial antiretroviral therapy commencing
between the years of 1997 and 2001, independently of age. Findings of theMoCAwere not confounded by existingmood disorders,
unlike the 3-item questionnaire. Therefore, we suggest implementing the MoCA as an initial screen for NCI.
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Access to potent and tolerable combination anti-retroviral therapy (cART) has positively changed the
health outlook for people living with HIV. However,
despite effective treatment, there is increasing awareness
of mild forms of neurocognitive impairment (NCI) af-
fecting relatively young individuals living with HIV
(Heaton et al., 2010). Determining whether cognitive
impairment is attributable to the virus, to other aspects of
treatment, and/or to comorbidities such as cardiovascular
diseases is important for persons livingwithHIV (PLWH)
and health care providers.
Neurocognitive complications of HIV infection were
recognized by clinicians as early as 1986 when PLWH in
the late stages of HIV infection presented with dementia-
like symptoms (Schouten, Cinque, Gisslen, Reiss, & Port-
egies, 2011). Postmortem brain studies conducted in that
era indicated that harmful pathology was likely driven
directly by viral proteins and neurochemically by secreted
neurotoxins and other cellular products (Gelman et al.,
2013; Schouten et al., 2011). Later, it was recognized that
the virus could persist in CD41T cells, macrophages, and
astrocytes, even in thecontextofapparently effective cART
introduced in the mid-1990s, creating a reservoir of “la-
tent” infection (Deeks, Lewin, & Havlir, 2013; Simoes &
Justino, 2015). Subsequently, concerns arose that anti-
retroviral penetration of the brainwas possibly limited and
varied between drug classes. A ranking of antiretroviral
drugs, according to their capacity to cross the blood brain
barrier and penetrate the central nervous system (CNS),
was suggested to optimize the efficacy of combined regi-
mens, and this ranking became known as the CNS pene-
tration effect (CPE) score (Cusini et al., 2013; Letendre
et al., 2008). However, some controversy continues as to
whether neuronal damage occurs as a result of anti-
retroviral toxicity. Other researchers have reported that
NCI can be associated with low CD41T cell counts, car-
diovascular diseases, metabolic disorders, and substance
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use (Anand, Springer, Copenhaver,&Altice, 2010; Simoes
& Justino, 2015; Tedaldi, Minniti, & Fischer, 2015). Cur-
rent cART is optimized to take into consideration the ca-
pacity of the virus to establish latent reservoirs in the brain.
Relevant for diagnosis and management of HIV-
associated neurocognitive disorders are the potential
confounding influences presented by the complex social
and psychological dimensions of living with HIV, which
can have a detrimental effect on health-related quality of
life (HRQL), activities of daily living, mood and be-
havior, stable employment, and interpersonal relation-
ships (Tedaldi et al., 2015). Importantly, NCI may
particularly impact medication adherence, the keystone
of effective viral suppression, as well as safe dosing
(Kamal et al., 2017). Nurses, frontline clinicians caring
for people living with chronic HIV, are well placed to
implement screening that can detect early, and poten-
tially fluctuating, neurocognitive deficits. Interventions
to optimize brain health and quality of life can then be
implemented. However, nurses need clear guidance
concerning valid assessment tools that can be feasibly
incorporated into routine care (Simoes&Justino, 2015).
The reportedprevalence ofHIV-associatedNCIvaries
between studies with rates varying between 15% and
50% among PLWH (Schouten et al., 2011). However,
severe forms of HIV-associated NCI are uncommon in
the context of effective cART (Heaton et al., 2010;
Tedaldi et al., 2015). Clinically, a subcortical profile of
NCI is characterized by mental slowness and deficits in
attention, memory, and executive functioning. These
symptoms may be accompanied by impairment of fine
motor skills, but in mild cases symptoms may not be
apparent (Brew & Chan, 2014; Heaton et al., 2004).
In a busy practice environment, health care providers
require brief, validated, and discriminating screening tools
to support clinical decisionmaking. However, expertise in
their administration and interpretation may be lacking
(Brouillette et al., 2014; Simoes & Justino, 2015). A
number of screening tools to assess NCI have been pro-
posed (Zipursky et al., 2013), including the CogState
(Bloch et al., 2016) and the Montreal Cognitive Assess-
ment (MoCA; Fazeli, Casaletto, Paolillo, Moore, &
Moore,2017).TheEuropeanAIDSClinical Society (2015)
provides comprehensive guidelines for HIV management
and recommends an initial screening for NCI that is com-
prised of three questions pertaining tomemory, reasoning,
and attention. Responses to these questions initiate a cas-
cade of decision making, beginning with an assessment of
depression/anxiety as a possible underlying cause, prior to
undertaking any further assessment of cognitive function.
Consideration of these guidelines underpinned this
study, which sought to identify individuals with early
cognitive changes in an aging cohort of PLWH attending
a community-based specialistHIV clinic, staffed by anurse
and an infectious disease physician.We aimed to (a) assess
the utility of the three-item cognitive concerns question-
naire (CCQ), as recommended by the European AIDS
Clinical Society, alongside the MoCA, a brief screening
instrument for mild cognitive impairment that had been
used in geriatric populations (Nasreddine et al., 2005); (b)
determine indicators of early NCI; and (c) assess the re-
lationship between psychological distress, impaired cog-
nitive performance, andHRQL.We considered that, from
aclinical perspective, these assessmentswouldbehelpful in
establishing baseline parameters against which we could
monitor future changes in the individual patient.
Methods
Participants
Fifty-eight adult PLWH attending the clinic at the In-
stitute for Immunology and Infectious Diseases at
Murdoch University (Perth, Australia) for management
of chronicHIV infectionwere recruited for participation
in the study, which ran from September 2015 to De-
cember 2016. This convenience sample comprised more
than 90% of clinic attendees visiting at 4-month inter-
vals and who received a nurse consultation prior to
seeing their HIV physician. During these consultations,
adherence to medication, psychosocial issues, diet, and
lifestyle were discussed; and blood pressure, weight, and
records concerning comorbid medical conditions were
updated. At this time, patients were offered the study
information, which they took home to consider, and
subsequently gave consent to participate in writing. At
subsequent visits, participants were asked to complete
a set of four validated instruments assessing neuro-
cognition, mood (depression, anxiety, and stress), and
HRQL prior to clinic consultations. Three of the
instruments were self-report questionnaires and were
completed independently by the participants, and the
fourth, the MoCA, was administered by nurses or
postgraduate clinical psychology students who were
trained to conduct the data collection. The study was
approved by the Murdoch University Human Research
Ethics Committee (Reference ID: 2015-112).
Measurement
Three-item cognitive concerns questionnaire. The
three-item questionnaire recommended in the European
AIDS Clinical Society Guidelines (2015) for use as an
initial screen for neurocognitive deficits in HIV infection
was derived from the HIV Dementia Scale (Power,
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Selnes, Grim, & McArthur, 1995). For the purposes of
clarity in this study, we refer to this screen as the cogni-
tive concerns questionnaire or the CCQ. The three
questions are as follows: (a) Do you experience frequent
memory loss (e.g., do you forget the occurrence of special
events, even the more recent ones, appointments, etc.?).
(b) Do you feel you are slower when reasoning, planning
activities, or solving problems? (c) Do you have diffi-
culties paying attention (e.g., to a conversation, a book,
a movie)? The questions are designed to elicit cognitive
complaintswith respondents indicating the presence and
frequency of such difficulties. An answer is considered
“actionable” when the response is yes, definitely to at
least one question. In addition to this clinic-based as-
sessment of the need for further follow-up,we calculated
the sum of the three responses to the three-item ques-
tionnaire as: 0 if never, one if sometimes, and two if yes,
definitely to obtain a score ranging from 0 to 6 for the
frequency of cognitive concerns as expressed at that visit.
The Montreal Cognitive Assessment. The MoCA
(Nasreddine et al., 2005) is a brief screen used in varied
clinical contexts, including HIV infection, to assess
cognitive domains, including attention, memory, con-
ceptual thinking, and orientation. The test is brief and
takes about 10–12 min to complete. The test taker is
asked to complete a series of tasks that assess short-term
memory, visuospatial ability, abstract reasoning, con-
centration, and language abilities. Each of these tasks is
scored separately, and themaximumpossible total is 30/
30 points with scores 26 and above indicating better
cognitive functioning. Accordingly, consistent with the
scoring guide for the instrument and its use by other
researchers, we considered a score of less than 26 as
being “actionable” and suggestive of a degree of cogni-
tive impairment. Staff were trained to administer the
MoCA, and alternative versions of the validated in-
strument containing slightly modified content, for ex-
ample the choice of words in a five-word delayed recall,
butmeasuring the same domains, were used at each visit.
This was done to minimize the likelihood of the test re-
sult being affected by the participants’previous use of the
instrument.
The Depression Anxiety Stress Scales. The De-
pression Anxiety Stress Scales (DASS) (Lovibond &
Lovibond, 1995) is a self-report instrument to assess
psychological distress across the domains of de-
pression, anxiety, and stress. Scores are calculated
across domains, with higher scores indicating higher
levels of distress. The questionnaire can be completed in
a 42- or 21-item format over 5–10 min. A four-point
response scale rates severity and frequency. The scores
ranged from 0, meaning that the patient believed the
item “did not apply to them at all,” to 3, meaning that
the respondent considered the item to “apply to them
very much, or most of the time.” Domain scores are
categorized by general population percentiles (normal:
,78th percentile, mild: 78th–87th percentile, moder-
ate: 87th–95th, severe: 95th–98th, extremely severe:
.98th), with scores above the 78th percentile consid-
ered to be clinically significant. For the analysis here, we
utilized z-scores as normalized by insertion of appro-
priate general population domain parameters (Craw-
ford, Cayley, Lovibond,Wilson, &Hartley, 2011) into
the formula: z-score 5 (raw score 2 domain mean)/
(domain standard deviation [SD]).
ThePatient-ReportedOutcomes&Health-Related
Quality of Life instrument specific for HIV. The PRO-
QOL-HIV (Duracinsky et al., 2012) is a self-report
questionnaire used to assess the HRQL of people living
with HIV. It reflects people’s perceptions over the
previous 2 weeks, and a five-point scale rates either
frequencyor level of agreement.There isoneglobal health
self-report itemand a further 32 questions reflecting three
global dimensions: physical health, psychological health,
and social health. The fourth dimension (10 items),
encapsulating treatment impact, can be omitted without
affecting the instrument’s psychometric properties; thus,
the instrument is equally valid forusebypeoplenot taking
cART. The subscale scores are summed and expressed as
a final score on a 0–100 scale with higher values
indicating better HRQL.
Central nervous system penetration effect. The
CNS penetration effect score for participants’ current
cART was calculated for each visit. These scores were
derived by summing assigned values of 1—below av-
erage, 2—average, 3—above average, and 4—much
above average to each component antiretroviral drug
according to the criteria established by Letendre et al.
(2008).
Statistical Analysis
Positive indication of NCI was defined by the “action-
ability” of the screening measures: The CCQ was
deemed actionable when any of the three items had
a response of yes, definitely, while the MoCA was
deemed actionable for a score less than 26. The pro-
portion of positive agreement between responses to the
CCQandMoCAscreening toolswas calculated as stated
in, for example, Spitzer and Fleiss (1974): (2 3 number
both screens actionable)/(number of CCQ actionable1
number MoCA actionable). Actionability of screening
responses at study entry according to demographics, and
the baseline clinical and psychological characteristics of
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participants were assessed by Fisher’s exact test and
analysis of variance as appropriate.
Mixed effect regression models, which can accom-
modate a varying number of visits per person, were
utilized for longitudinal analyses of the screening
assessments, the MoCA and cognitive concerns fre-
quency scores, and associations with measures of psy-
chological distress. The models assumed individual
measures fluctuate from visit to visit about patient-
average values, which may in turn vary around group
means or trendover time, or according to other covariate
values. Assessment of bivariate associationswithHRQL
wasbasedonPearson correlation coefficients, calculated
from the respective individual mean measures. p Values
#.05 were considered statistically significant.
Baseline actionability comparisons and regression
analyses included consideration of the impact of de-
mographic characteristics (age, sex, race), psychological
characteristics (diagnosed depression, DASS scores),
and baseline clinical measures (years since diagnosis and
treatment start date, CD41T cell measures, CPE score).
In a reflection of changing cohort prescribing practices
over the years, era of treatment initiation was also con-
sidered in analyses, as defined by the calendar periods of
1990–1996 (pre-cART), 1997–2001 (early cART), and
2002–2014 (later cART).
Results
Data that included concurrent responses to the NCI
screening tools and the DASS and PROQOL ques-
tionnaires were obtained from 58 individuals (87%
male) over 1–3 visits per person (M 5 2), approxi-
mately 4 months apart to coincide with clinic visits. At
baseline, patients had a mean (SD) age of 57 (9) years
and time since diagnosis ranged from 2 to 32 (M5 19)
years. All patients were receiving effective cART and
had undetectable plasma viral loads. More females
than males were non-Caucasian (6/9 5 67% vs. 9/49
5 18%, p 5 .006 Fisher’s test). Prevalence of docu-
mented depression was similar between males and
females (18% vs. 22%, p . .9), and at the time of the
study, none of the participants were diagnosed with
dementia or any other neurological disorder.
Relative Frequency of Actionable Responses to
theMontrealCognitiveAssessment andCognitive
Concerns Questionnaire
There was low overall agreement between the MoCA
and CCQ as indicators of NCI, with the proportion of
positive agreement in the contemporaneous screening
assessments being approximately 25%. In particular,
54/115 (47%) ofMoCA results, which ranged from 17
to 30, fell below the threshold of 26, as compared to
the 25/115 (21.7%) of actionable responses to the
CCQ. In all, while at least one below-thresholdMoCA
screen was observed in 63.8% (37/58) of study par-
ticipants, and at least one actionable CCQ result in
32.8% (19/58) of participants, there were only 10
individuals (17.2%) in whom neurocognitive dys-
function was indicated by both screens. Furthermore,
patient-average MoCA scores (M [SD] 5 25.4 [2.7])
showed little correlation with the average CCQ fre-
quency scores (R 5 0.11).
Clinical and Demographic Indicators of
Neurocognitive Impairment
No baseline clinical and demographic variables showed
a consistent association with positive outcomes across
the two screening measures at study entry (Table 1). Age
was the strongest predictor of an actionable CCQ re-
sponse (p 5 .03) but did not significantly differentiate
the MoCA responses. However, older age particularly
characterized those with concordant indication of NCI
by both screens (both CCQ and MoCA positive at
baseline: n 5 7, M [standard error] age 5 63.9 [2.4]
years; neither screen positive: n5 20, 53.2 [2.0] years; p
5 .004). There was a strong association between the era
of commencing therapy and likelihood of an actionable
MoCA response at baseline (p 5 .002). In particular,
a lower MoCA score at baseline was observed in those
whose initial therapy was in the era of early cART
(1997–2001) independently of age, time since diagnosis,
or length of time on treatment (p , .003, linear re-
gression analyses). Notably, more than 75% of patients
who had commenced initial treatment in the early cART
era (1997–2001) scored below the MoCA threshold,
a finding that did not appear to be driven by older age
(Figure 1).
In the longitudinal analysis, era of therapy initiation
remained strongly associated with scoring on the MoCA
(p5 .005; estimatedM[standard error] score 1990–1996:
26.4 [0.6], 1997–2001: 24.1 [0.6], 2002–2014: 25.8
[0.5]), but not frequency of cognitive concerns (p5 .2). A
below-threshold MoCA result was more prevalent in
patients who commenced therapy in the earlier years of
cART (1997–2001), irrespective of age, with patients
starting treatment in this era significantly more likely to
have an actionable response than those whose first anti-
retroviral therapy was pre-cART (odds ratio [OR] 5 3.4,
p 5 .04; age-adjusted: OR 5 3.7, p 5 .03) or those who
commenced treatment after 2001 (OR 5 5.6, p 5 .003;
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age-adjusted: OR 5 5.3, p 5 .003). For both screens,
neither antiretroviral regimen nor any of the CD41
measures were associated with odds of returning an
actionable result, eitherwith orwithout adjustment for age
or treatment era, nor were there significant trends in time
over the period considered.
Table 1. Actionability of Screening Responses at Study Entry According to Demographics and Baseline
Clinical and Psychological Characteristics of Individuals




p-Valuecn 5 40 n 5 18 n 5 31 n 5 27
Demographics
Male gender (vs. female) 31 (77.5%) 18 (100.0%) .05 28 (90.3%) 21 (77.8%) .3
Caucasian race (vs. other) 28 (70.0%) 15 (83.3%) .3 25 (80.6%) 18 (66.7%) .2
Era of therapy initiation .4 .002
Prior to 1997 (pre-cART) 9 (22.5%) 7 (38.9%) 10 (32.3%) 6 (22.2%)
1997–2001 (early cART) 14 (35%) 5 (27.8%) 4 (12.9%) 15 (55.6%)
2002–2014 17 (42.5%) 6 (33.3%) 17 (54.8%) 6 (22.2%)
Documented depression 5 (12.5%) 6 (33.3%) .08 8 (25.8%) 3 (11.1%) .2
Baseline characteristics
Age (years) 54.736 8.3 61.476 10.5 .03 55.10 6 10.6 57.636 7.7 .3
Years since diagnosis 17.476 8.1 19.886 10.4 .5 16.83 6 10.1 19.826 6.9 .2
Years on therapy 14.386 6.6 16.376 8.3 .5 13.58 6 8.2 16.636 5.5 .1
Antiretroviral regimen .7 .7
NNRTI-based 22 (55%) 8 (44.4%) 17 (54.8%) 13 (48.1%)
PI-based 6 (15%) 4 (22.2%) 6 (19.4%) 4 (14.8%)
Otherd 12 (30%) 6 (33.3%) 8 (25.8%) 10 (37.0%)
CPE score 8.07 6 1.2 7.5 6 1.5 .08 7.87 6 1.2 7.93 6 1.4 .9
Nadir CD41 T cells/mm3 303 6 155 2466 178 .2 280 6 175 291 6 152 .8
Nadir CD41% of lymphocytes 17.4 6 8.4 15.0 6 8.8 .3 15.6 6 9.2 17.8 6 7.7 .3
CD41 T cell count/mm3 795 6 344 6916 306 .3 723 6 377 810 6 278 .3
CD41% of lymphocytes 35.46 8.4 32.6 6 10.7 .4 33.2 6 8.9 36.2 6 9.4 .2
CD41/CD81T cell ratio 1.02 6 0.4 0.93 6 0.5 .5 0.93 6 0.5 1.07 6 0.5 .2
Depression z-scoree 20.20 6 0.80 0.70 6 1.42 .01 0.22 6 1.04 0.06 6 1.15 .6
Anxiety z-scoree 20.07 6 0.52 0.56 6 1.51 .01 0.08 6 0.65 0.19 6 1.27 .7
Stress z-scoree 20.10 6 0.14 20.15 6 0.16 .22 20.11 6 0.10 20.12 6 0.18 .9
Note. Data values are n (%) orM 6 standard deviation. cART5 combination antiretroviral therapy; CPE5 central nervous system
penetration effect; NNRTI 5 non-nucleoside reverse transcriptase inhibitor; PI 5 protease inhibitor.
a Ananswer is considered “actionable” in thecognitive concernsquestionnairewhen the response is “yes, definitely” to at least onequestion.
b The Montreal Cognitive Assessment is deemed positive for a score , 26.
c p Values are derived from comparisons assessed by Fisher’s exact test or analysis of variance.
d Includes individuals who were on both PI and NNRTI drugs.
e Derived from normalized scores of the Depression Anxiety Stress Scales (DASS).
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Prevalence of Psychological Distress and Impact
on Neurocognitive Impairment
Psychological distress was notably prevalent in the co-
hort; observed rates of clinically significant symptoms of
depression and anxiety, as profiled by responses to the
DASS at study entry were 21% and 15%, respectively.
Individuals with an actionable response to the three-item
CCQ screening questions were more likely to report
greater psychological distress, with higher scores in both
the depression and anxiety domains compared with
patients with nonactionable responses (p5 .007 and p5
.02, respectively). Of the CCQ-actionable responses at
baseline, 7/18 (39%) and 4/18 (22%) coincided with
DASS scores indicative of clinically significant depression
andanxiety, respectively. In contrast to theCCQ,baseline
indication of NCI by the MoCA did not associate with
higher scores across any of the domains (p. .5).
In longitudinal analyses, impact of psychological dis-
tress on performance in the CCQ screening test was
particularly apparent in younger patients. Notably, in-
creased anxiety and depressive symptomology were as-
sociated with having an actionable CCQ screen among
patients with ages younger than 60 years (p5 .004 and p
5 .01, respectively). The impact of mood on MoCA
results was less marked; although average scores were
moderately lower when patients reported increased anx-
iety levels (p 5 .04, adjusted for age and era of therapy
initiation), there was no significant association between
theMoCA scores and depressive symptomology (p. .6).
Health-Related Quality of Life Correlations with
Psychological Distress and
Neurocognitive Impairment
Patient-average HRQLmeasures across physical health,
psychological health, and social health domains were
significantly correlated with the mean self-reported
psychological distress scores as measured by the three
DASS scales (p # .0001). Overall HRQL, and particu-
larly general psychological health, was notably reduced
in patients reporting the most depressive symptoms
(R 5 20.81 and R 5 20.76, respectively, p , .0001).
Increased frequency of self-reported cognitive concerns
was also significantly associated with poorer HRQL (p
5 .002), correlating inversely with both the physical and
social domains (R520.59, p,. 0001, andR520.36,
p 5 .005, respectively). This was in contrast to the
MoCA results, which failed to show any significant re-
lationship with HRQL measures.
Discussion
In this study, the three-item self-report questionnaire
addressing patients’ cognitive concerns, which was rec-
ommended by the European AIDS Clinical Society as an
initial assessment for HIV-associatedNCI, showed poor
concordance with performance on the MoCA. The dis-
crepancy between the two screens calls into question the
utility of theCCQas a“procedural” step in the screening
for NCI, at least its ability to discriminate early asymp-
tomatic cognitive impairment. Of note, the CCQ in-
dicated that about one third of patients may have
subjective memory or other cognitive complaints, but
these scores were more closely associated with
depression/anxiety and HRQL. In contrast, about two
thirds of the cohort had subthreshold (,26) scores with
the MoCA screen, a validated instrument for detecting
asymptomatic NCI in patients ages 50–60 years (Fazeli
et al., 2017), and these results were found to be largely
independent of coexisting psychological factors. These
findings suggest prevalent and largely asymptomatic
NCI in our cohort, notably in patients who commenced
therapy in the cART era defined by the years from 1997
to 2001.
The threshold chosen for theMoCA is consistent with
the recommended application of the tool as a brief screen
for mild cognitive impairment in a geriatric population
(Nasreddine et al., 2005) and has subsequently been
used in the HIV context (Janssen, Bosch, Koopmans, &
Kessels, 2015; Milanini et al., 2014; Simoes & Justino,
2015). This threshold could be considered conservative
in comparison with the study of Fazeli et al. (2017) in
which a cutoff of#26was used; however, the sensitivity
observed in their study of 84.2% was balanced by a re-
duced specificity of 55.8%. Accordingly, while we may
have missed some cases of early NCI by the use of the
higher cutoff, it is less likely that NCI was incorrectly
assigned due to a reduced specificity.
Figure 1. Comparison between the three-item CCQ and the MoCA as
indicators of neurocognitive impairment according to era of first treatment
and age category (data from baseline scores). CCQ5 cognitive concerns
questionnaire; MoCA5Montreal Cognitive Assessment.
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We acknowledge that the NCI observed in some
participants cannot be attributed to HIV-related causes
alone, because older participants had more consistent
associations with both screens. However, it is notewor-
thy that patients who commenced therapy in the early
cART era (1997–2001) were more likely to return an
impaired MoCA score than those commencing drugs in
pre-cART (prior to 1997) or later cART (after 2001)
eras, and this association persisted even after adjusting
for age. This finding is not altogether surprising. Al-
though the incidence of HIV-associated dementia has
fallen following the introduction of potent combina-
tions, early studies found that neuropsychological defi-
cits remained common, indicating an active and
damaging intracerebral process (Cysique, Maruff, &
Brew, 2004; Heaton et al., 2010; Sacktor et al., 2002).
Later, studies of larger cohorts (Heaton et al., 2011),
defined by era of cART (1988–1995 vs. 2000–2007) and
disease stage, showed a different pattern of impairment
between eras. Our current study delineates these three
eras and reflects antiretroviral prescribing practices in
our clinical context. Our finding is consistent with the
current thinking that latent virus, which is established
when infected monocytes and lymphocytes cross the
blood brain barrier, activates ongoing systemic in-
flammation (Deeks et al., 2013). Subsequently, the
unique immunological compartment of the CNS shapes
host–virus interaction, leading to a differential response
to treatment, distinct from the peripheral circulation.
This understanding provided a plausible explanation for
viremia in cerebrospinal fluid in the context of otherwise
suppressive cART (Strain et al., 2005) and led to the
development of the antiretroviral CPE ranking scale to
guide the selection of regimens protective of the brain
(Letendre et al., 2008). The guidelines for starting cART
in the late 1990s recommended delaying treatment until
the CD41 T cell count fell to 200 mm3/L; therefore, it is
likely that our participants would have established la-
tency in the CNS, which drove systemic inflammation.
Furthermore, the recommended first-line regimens at
the time included the lowly CPE-ranked nelfinavir
and saquinavir, with a backbone of stavudine and
didanosine or lamivudine, nucleosides having a neuro-
penetrance capacity inferior to that of zidovudine and
abacavir (Letendre et al., 2008). In contrast, those par-
ticipants who had received monotherapy before the in-
troduction of cART, and earlier in their disease
trajectory, may have benefited from the strong neuro-
protective effect of zidovudine.
In addition to prolonged CNS exposure to virus,
suboptimal adherence to early cART may also have
contributed to the development of NCI (Castillo-
Mancilla et al., 2016). Early combination drug regimens
were tissue toxic, particularly affectingmitochondria and
metabolic pathways (John,Mallal,&French, 1998),with
frequent and multiple adverse side effects, especially
gastrointestinal (Mocroft et al., 2001).Our observational
study in 2002 (Herrmann et al., 2008) showed that more
than 50% of patients reported missed doses in the month
prior to their appointment, but by 2008, only 18% of
patients in the same cohort reported less than 100% ad-
herence. An alternative explanation is that neurotoxicity
was induced by antiretrovirals used in that era (Caniglia
et al., 2014; Underwood, Robertson, &Winston, 2015).
This theory arose because studies, in vitro, showed that
intracellular accumulation of toxic proteins arising from
proteosome dysfunction, and caused by protease inhib-
itors, could be a mechanism for cell damage. Equally, it
was thought that efavirenzmaybeneurotoxic, but studies
are conflicting (Caniglia et al., 2014; Letendre, Ellis,
Ances, &McCutchan, 2010).
Limitations
Firstly, the patient cohort was relatively small and, there-
fore, may have lacked power to detect associations with
T cell measures, and the ability to assess categorical asso-
ciations of NCI with cardiovascular diseases, metabolic
disorders, and history of substance use, as observed by
others. However, our observations were able to confirm
the findings seen in larger studies in other contexts. Sec-
ondly, althoughour study did not include anHIV-negative
control group, our data are enriched by the comprehensive
clinical and treatment histories of the participants and
continued follow-up over time, which will benefit in-
dividual patients and informfuture cohort studies.Thirdly,
not all participants contributed longitudinal data, and the
16-month study periodwas too short to assess the stability
of the neurocognitive status or the trajectory of any decline
in relation to age. Lastly, information on family history of
dementia and other risk markers was lacking.
Conclusions
Our study points to the MoCA as a useful screen for
detecting early NCI and has found it to be largely un-
affected by associated depression or anxiety, whereas
reliance on the self-reported CCQ alone appears an in-
adequate strategy. Addressing psychological distress is
a key component of HIVmanagement, and clarifying the
potential contribution of depression/anxiety, common in
people living with HIV, is necessary when assessing neu-
rocognitive function. Of concern for many patients, is
uncertainty about the future and aging in the context of
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HIV infection. We suggest the MoCA be administered
with the DASS to discriminate impaired neurocognitive
functioning from mood disorders and identify patients
whomay require further psychological assessment and/or
specialist referral. These screening tools are simple and
quick to administer in a practice setting, and the imme-
diacy of the feedback may serve to either validate or al-
leviate patient concerns. Furthermore, this can provide
nurses with an opportunity to engage patients in a dis-
cussion of lifestyle interventions such as exercise and so-
cial engagement. Finally, based on our findings, we
recommend monitoring HRQL on a regular basis to
complement theMoCA and the DASS and to reveal early
cues that something is amiss. This holistic approach is
feasible in a community practice setting.
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